(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 5.21% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.06%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Merck & Co's revenue in 2026 is $65,011,000,000.On average, 31 Wall Street analysts forecast MRK's revenue for 2026 to be $166,738,116,682,320, with the lowest MRK revenue forecast at $160,117,050,898,286, and the highest MRK revenue forecast at $175,109,636,004,478. On average, 30 Wall Street analysts forecast MRK's revenue for 2027 to be $175,851,353,605,378, with the lowest MRK revenue forecast at $162,564,718,981,256, and the highest MRK revenue forecast at $187,580,381,267,610.
In 2028, MRK is forecast to generate $187,746,031,531,811 in revenue, with the lowest revenue forecast at $174,011,893,955,146 and the highest revenue forecast at $207,025,744,371,205.